Nanovibronix Inc Stock Price, News & Analysis

NanoVibronix (NASDAQ: NAOV) announced that a major 420-bed acute care hospital in New Orleans has selected its ENvue™ Navigation Platform for feeding tube procedures. The hospital will transition from traditional blind insertions to the FDA-cleared electromagnetic guidance system, which enables real-time visualization of tube direction and positioning during placement.

The ENvue System has already been shipped to the facility, with on-site implementation scheduled soon. This marks ENvue Medical's first entry into the Louisiana market, with additional hospital implementations being prepared across multiple U.S. regions.

NanoVibronix (NASDAQ: NAOV), a medical technology company, has closed its public offering of 400,000 shares of Series G Convertible Preferred Stock and Warrants, raising $10 million in gross proceeds. The offering included Preferred Stock at $25 per share and Warrants to purchase up to 4,901,982 common shares at $2.04 per share.

Key terms include 9% cumulative dividends on Preferred Stock payable in up to 2,205,883 common shares, and five-year Warrants exercisable immediately. The company plans to use proceeds to redeem a $1.3 million debenture from February 2025, partially repay a $2.497 million note from January 2025, and for general corporate purposes. Dawson James Securities served as the sole bookrunning manager.

NanoVibronix (NASDAQ: NAOV), a medical technology company, has announced the pricing of a $10 million public offering consisting of approximately 400,000 shares of Series G Convertible Preferred Stock and Warrants. Each unit, priced at $25.00, includes Preferred Stock and Warrants to purchase up to 4,901,961 common shares at an exercise price of $2.04 per share.

The offering, managed by Dawson James Securities, is expected to close around May 19, 2025. The company plans to use the proceeds to redeem $1.3 million in outstanding debentures, allocate $700,000 for partial repayment of a $2.49 million note, with the remainder for general corporate purposes.

NanoVibronix (NASDAQ: NAOV) has released promising results from a retrospective case series evaluating their UroShield™ system at University Hospitals Coventry and Warwickshire Partnership NHS. The study, conducted between September 2023 and January 2025, demonstrated significant clinical benefits including a 94% reduction in catheter-associated urinary tract infections (CAUTIs) and catheter blockages, and a 92% decrease in unplanned hospital visits. The UroShield device, which uses Surface Acoustic Wave (SAW) technology to prevent bacterial colonization on urinary catheters, showed high patient compliance and satisfaction. Only one patient discontinued use due to worsening pre-existing symptoms. These results align with previous studies by Markowitz et al. (2018) and Da Silva et al. (2021), further validating the device's effectiveness. The findings will be presented at the ACP 2025 conference on May 19, 2025.

NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has successfully regained full compliance with Nasdaq listing requirements. The company received formal notification from Nasdaq on April 9, 2025, confirming it has met all criteria for continued listing on The Nasdaq Capital Market, including the critical $1.00 bid price and $2.5 million stockholders' equity requirements.

The previously disclosed listing concern has been resolved, though the company will remain under a Mandatory Panel Monitor until April 9, 2026.

NanoVibronix (NASDAQ: NAOV) has renewed and expanded its exclusive three-year distribution agreement with Dukehill Healthcare for its UroShield device across all Australian States. The agreement, previously focused on Queensland and New South Wales, now extends to South Australia and Victoria following increased healthcare facility inquiries.

The expansion comes after the publication of an independent study highlighting UroShield's effectiveness in reducing catheter-associated complications and improving patient outcomes. Dukehill will showcase UroShield at the 33rd National Conference on Incontinence in Hobart in May 2025, where clinicians will discuss the study findings.

NanoVibronix (NASDAQ: NAOV) announced the publication of an independent health service study of its UroShield® device in The Australian and New Zealand Continence Journal. The study demonstrated significant improvements in patient care and cost reduction for those with indwelling urinary catheters.

Key findings include:

• 86% reduction in UTI incidence
• 70% reduction in catheter blockages
• 82.8% decrease in bladder irrigations
• 52.3% reduction in catheter changes
• 63.5% reduction in resource costs over 5 months

The study, conducted by a New Zealand District Nursing Service, highlighted UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and improving patient comfort while reducing healthcare provider costs through decreased nursing time and fewer interventions.

NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has announced a 1-for-11 reverse stock split effective March 13, 2025. The stock will begin trading on a split-adjusted basis on March 14, 2025, maintaining its NASDAQ symbol NAOV.

The reverse split, approved by stockholders on February 24, 2025, will reduce outstanding shares from 8,716,327 to approximately 792,394. The conversion will be automatic, with fractional shares rounded up to the nearest whole number. The split will not alter stockholders' percentage ownership in the company.

Proportional adjustments will be made to equity awards, warrants, and other convertible securities. The company's common stock will trade under a new CUSIP number: 63008J702.

NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has completed the acquisition of ENvue Medical Holdings Corp., a private company specializing in enteral feeding solutions. The strategic acquisition aims to strengthen the combined company's market position in enteral feeding technology and therapeutic medical devices.

The merger is expected to leverage ENvue's proprietary technology alongside NanoVibronix's existing portfolio, creating a broader commercial platform with enhanced distribution and operational efficiencies. The combined entity will focus on addressing patient safety challenges in enteral feeding while expanding market reach in the medical device sector.